John M Bennett| - JoVE Visualize

Showing results (61-70 of 131) with videos related to

Pageof 14

Sort By:

Leukemia Research|December 7, 2007

Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based surveyDavid P Steensma, Kathleen V Heptinstall, Victor M Johnson, et al.

Leukemia Research|July 26, 2011

Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literatureRahel A Mathew, John M Bennett, Jane Jijun Liu, et al.

Cancer|July 12, 2008

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemHagop Kantarjian, Susan O'Brien, Farhad Ravandi, et al.

Blood|August 19, 2010

Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999Larry D Cripe, Hajime Uno, Elisabeth M Paietta, et al.

Haematologica|April 16, 2013

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trialSteven D Gore, Pierre Fenaux, Valeria Santini, et al.

Blood|March 27, 2004

Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemiasElisabeth Paietta, Adolfo A Ferrando, Donna Neuberg, et al.

British Journal of Haematology|January 29, 2014

Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromesJohn F Seymour, John M Bennett, Alan F List, et al.

Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2013

Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemiaAdam W Mailloux, Ling Zhang, Lynn Moscinski, et al.

Cancer|July 2, 2003

Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology GroupArthur I Radin, Haesook T Kim, Barbara W Grant, et al.

Cancers|April 26, 2025

Association Between B-Cell Marker Expression and RUNX1 Lesions in Acute Myeloid Leukemia, Beyond RUNX1::RUNX1T1 Fusion: Diagnostic Pitfalls with Mixed-Phenotype Acute Leukemia-B/MyeloidGiby V George, Malgorzata Kajstura, Audrey N Jajosky, et al.

Pageof 14

Showing results (61-70 of 131) with videos related to

Sort By:

Pageof 14

Leukemia Research|December 7, 2007

Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based surveyDavid P Steensma, Kathleen V Heptinstall, Victor M Johnson, et al.

Leukemia Research|July 26, 2011

Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literatureRahel A Mathew, John M Bennett, Jane Jijun Liu, et al.

Cancer|July 12, 2008

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemHagop Kantarjian, Susan O'Brien, Farhad Ravandi, et al.

Blood|August 19, 2010

Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999Larry D Cripe, Hajime Uno, Elisabeth M Paietta, et al.

Haematologica|April 16, 2013

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trialSteven D Gore, Pierre Fenaux, Valeria Santini, et al.

Blood|March 27, 2004

Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemiasElisabeth Paietta, Adolfo A Ferrando, Donna Neuberg, et al.

British Journal of Haematology|January 29, 2014

Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromesJohn F Seymour, John M Bennett, Alan F List, et al.

Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2013

Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemiaAdam W Mailloux, Ling Zhang, Lynn Moscinski, et al.

Cancer|July 2, 2003

Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology GroupArthur I Radin, Haesook T Kim, Barbara W Grant, et al.

Cancers|April 26, 2025

Association Between B-Cell Marker Expression and RUNX1 Lesions in Acute Myeloid Leukemia, Beyond RUNX1::RUNX1T1 Fusion: Diagnostic Pitfalls with Mixed-Phenotype Acute Leukemia-B/MyeloidGiby V George, Malgorzata Kajstura, Audrey N Jajosky, et al.

Pageof 14